UNIGE document Scientific Article
previous document  unige:46003  next document
add to browser collection
Title

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

Authors
Emery, Paul
van Vollenhoven, Ronald
Dikranian, Ara
Alten, Rieke
Pavelka, Karel
Klearman, Micki
Musselman, David
show hidden authors show all authors [1 - 11]
Published in The Lancet. 2013, vol. 381, no. 9877, p. 1541-50
Abstract Roughly a third of patients with rheumatoid arthritis treated with biological treatments receive them as monotherapy. Tocilizumab--an inhibitor of interleukin 6 receptor signalling--has been studied as monotherapy in several clinical trials. We assessed the efficacy and safety of tocilizumab monotherapy compared with adalimumab monotherapy for patients with rheumatoid arthritis.
Keywords AdultAgedAntibodies, Monoclonal, Humanized/therapeutic useAntirheumatic Agents/therapeutic useArthritis, Rheumatoid/therapyDouble-Blind MethodFemaleHumansMaleMiddle Aged
Identifiers
PMID: 23515142
Full text
Article (Published version) (413 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Mécanisme de l'inflammation articulaire (44)
Citation
(ISO format)
GABAY, Cem et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. In: The Lancet, 2013, vol. 381, n° 9877, p. 1541-50. https://archive-ouverte.unige.ch/unige:46003

134 hits

0 download

Update

Deposited on : 2015-01-29

Export document
Format :
Citation style :